Transcatheter closure of a hemodynamically significant patent ductus arteriosus (hsPDA) is increasingly used as the definitive way to stop abnormal blood flow in very preterm infants. Yet clinicians still debate whether to wait and optimize stabilization first, or proceed promptly once closure becomes clearly indicated. The practical problem is timing: when a baby has a ductus that demands intervention, does earlier device occlusion prevent neonatal complications—or simply increase procedural risk?
Current guidance from pediatric and cardiovascular societies generally favors intervention for “high-volume” hsPDAs that persist beyond about 10–14 days after unsuccessful conservative care or failed pharmacologic therapy. Intervention is also recommended when medications are contraindicated, such as when specific clinical contraindications limit exposure to indomethacin or ibuprofen. These recommendations are consensus-based and aim to balance ductal persistence against the hazards of catheter procedures.
However, direct evidence pinpointing the optimal day to place the device remains scarce. Much of the available literature is observational, with substantial variation in inclusion criteria, ductal severity definitions, procedural technique, and infant baseline risk. As a result, studies often struggle to distinguish whether outcomes reflect timing itself or differences in illness severity that drive clinicians’ decisions.
The review emphasizes how timing may influence the biology of the ductus and the infant’s physiology. Delayed closure could allow ongoing left-to-right shunting, exposing organs to altered perfusion and inflammation. In contrast, earlier closure may occur before the infant’s pulmonary, hemodynamic, or coagulation status fully stabilizes, potentially increasing risks such as vascular access complications, device malposition, or post-procedural instability.
A key uncertainty is how timing affects morbidity trajectories. Clinicians care about outcomes including bronchopulmonary dysplasia, intraventricular hemorrhage, necrotizing enterocolitis, need for ongoing ventilation, and longer-term growth or cardiovascular adaptation. The review highlights that timing-related effects could be mediated by both shunt duration and the infant’s evolving capacity to tolerate interventions.
Ongoing trials are expected to provide stronger evidence by testing structured timing strategies and standardizing outcome measures. In the meantime, the authors propose a clinical decision framework: incorporate ductal hemodynamic burden, response—or lack of response—to medical therapy, gestational age, procedural feasibility, and evolving organ function, rather than relying on ductus duration alone.
The overarching message is that “early versus late” is not a single answer. Individualization may be necessary because infant fragility, ductal anatomy, and institutional expertise all interact with when closure is attempted. The field’s priority is to translate future trial results into actionable timing thresholds that reliably reduce morbidity without escalating procedural harm.
Ultimately, optimizing when device occlusion occurs could help shift practice from guideline-driven timing to evidence-based timing. That transition may improve survival and reduce avoidable neonatal complications by aligning intervention with both ductal persistence and infant readiness.
Subject of Research: Pediatric transcatheter device occlusion timing in preterm infants with hsPDA.
Article Title: Optimal timing for transcatheter device occlusion of a hemodynamically significant patent ductus arteriosus in preterm infants: evidence, uncertainty, and future directions.
Article References: Avades, M.J., Griffiths, P.S., Weems, M.F. et al. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02816-5
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41372-026-02816-5
Keywords:
